Exercise Treatment for Breast Cancer

Recruiting in Palo Alto (17 mi)

+12 other locations

Overseen byNeil Iyengar, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.

Research Team

Neil Iyengar, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who are sedentary and starting first-line endocrine therapy. They must be cleared for exercise, willing to follow study procedures, have a BMI of at least 18.5, and can't be in other exercise or weight loss programs or have a life expectancy under six months.

Inclusion Criteria

My breast cancer is HR-positive and HER2-negative.

You do not exercise regularly, meaning you do less than 60 minutes of exercise per week.

My brain lesions have been treated and stable for 2 months or more.

See 7 more

Exclusion Criteria

You are currently taking part in a weight loss or exercise program.

You have trouble understanding or following instructions.

You are not expected to live for more than 6 months.

See 1 more

Treatment Details

Interventions

Exercise Treatment (Behavioural Intervention)

Trial OverviewThe study is examining the effects of aerobic exercise alongside standard first-line treatment for metastatic breast cancer. The goal is to see if exercise can help delay resistance to hormone therapy and slow tumor growth.

Participant Groups

5Treatment groups

Experimental Treatment

Group I: aerobic training 90 mins/wkExperimental Treatment1 Intervention

Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.

Group II: aerobic training 375 mins/weekExperimental Treatment1 Intervention

Group III: aerobic training 300 mins/weekExperimental Treatment1 Intervention

Group IV: aerobic training 225 mins/wkExperimental Treatment1 Intervention

Group V: aerobic training 150 mins/wkExperimental Treatment1 Intervention